Newly Validated Q175 Knock-in Model Better Indicator of Huntington’s Disease Condition in Humans
June 8, 2012 - Huntington's disease (HD) is an autosomal neurodegenerative disorder, characterized by severe behavioral, cognitive and motor deficits. Several mouse models, including the R6/2 mouse, which expresses a truncated fragment of mHTT, have been generated to examine the pathogenesis of the disease in an effort to develop novel treatment options. The newly validated Q175 knock-in mouse, however, carries the mutation in its appropriate genomic and protein context, making it, mechanistically, the most true-to-life model of the human condition.
Charles River Discovery Research Services has licensed and validated the Q175 knock-in mouse model, a new tool for researchers investigating the effects of HD therapeutics. This model is a counterpart to the widely used R6/2 mouse line, which demonstrates very fast progression of HD-like symptoms. In contrast, the Q175 mouse develops symptoms early, and with slower progression, allowing ample time to observe the early events triggered by the mutation. Full manifestation of HD-like motor deficits and brain atrophy is apparent in homozygote mice from 3 months and in heterozygote littermates by 4 to 8 months of age. The robustness, gene dose-dependency, progression and early-onset alterations in the Q175 pathogenesis provide researchers with a longer window to detect chronic compound administration effects. Charles River’s mouse efficacy test paradigm includes behavior and cognition, in vivo magnetic resonance imaging (MRI) for brain volumetry and magnetic resonance spectroscopy (MRS) for brain metabolites. Additional testing services are described below.
Behavioral and Cognitive Tests for Huntington’s Disease
For more information about facilitating your Huntington’s disease study with Charles River’s Q175 knock-in model, please contact us at firstname.lastname@example.org.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
Charles River has developed and optimized the RT-PCR test for vertically-transmitted poultry pathogens for testing SPF flocks as defined by the PhEur 5.2.2.
mai 21–mai 24
RDD Europe 2013 is a forum for pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise.
mai 23–mai 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for leading sales program in assigned territory; assisting Account Management with presenting global capabilities, qualifying leads, demonstrating added value and closing new business opportunities by providing scientific support during sponsor teleconference calls, field visits and at scientific trade shows; providing technical leadership and direction to support customers and the Account Management and Global Accounts team; and working with Account Management and Global Account team to generate major account-specific sales strategies to close opportunities.
Charles River Laboratories, Inc.